Merck to Acquire VelosBio for $2.75B
Shots:
- Merck will acquire all the outstanding shares of VelosBio for $2.75B in cash. The transaction is expected to be closed by the end of 2020
- The acquisition will bolster Merck’s oncology pipeline with the addition of VelosBio’s VLS-101- which is an investigational ADC targeting ROR1 to treat hematological malignancies and solid tumors
- In Oct’2020- VelosBio has initiated P-II study to evaluate VLS-101 for the treatment of patients with solid tumors- including patients with TNBC- HR+/HER2+ BC- and NSCLC. Additionally- VelosBio is developing a preclinical pipeline of ADCs and bispecific Abs targeting ROR1 to complement VLS-101 by offering alternative methods of tumor cell killing
Ref: PRNewswire | Image: Merck
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com